Patents by Inventor Venkateshwar Rao Gummadi
Venkateshwar Rao Gummadi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11981685Abstract: The present invention provides bicyclic heterocyclyl kinase enzyme inhibitor compounds of formula (I), which are therapeutically useful as kinase inhibitors, particularly IRAK4 inhibitors. wherein A, Y, Z, X1, X2, X3, R1, R3, ‘m’, ‘n’ and ‘p’ have the meanings given in the specification and pharmaceutically acceptable salts or stereoisomers thereof that are useful in the treatment and prevention of diseases or disorders, in particular their use in diseases or disorders mediated by kinase enzyme, particularly IRAK4 enzyme. The present invention also provides pharmaceutical compositions comprising at least one of the compounds of compound of formula (I) together with a pharmaceutically acceptable carrier, diluent or excipient therefor.Type: GrantFiled: April 28, 2023Date of Patent: May 14, 2024Assignee: Aurigene Oncology LimitedInventors: Venkateshwar Rao Gummadi, Susanta Samajdar
-
Publication number: 20230331740Abstract: The present invention provides bicyclic heterocyclyl kinase enzyme inhibitor compounds of formula (I), which are therapeutically useful as kinase inhibitors, particularly IRAK4 inhibitors. wherein A, Y, Z, X1, X2, X3, R1, R3, ‘m’, ‘n’ and ‘p’ have the meanings given in the specification and pharmaceutically acceptable salts or stereoisomers thereof that are useful in the treatment and prevention of diseases or disorders, in particular their use in diseases or disorders mediated by kinase enzyme, particularly IRAK4 enzyme. The present invention also provides pharmaceutical compositions comprising at least one of the compounds of compound of formula (I) together with a pharmaceutically acceptable carrier, diluent or excipient therefor.Type: ApplicationFiled: April 28, 2023Publication date: October 19, 2023Inventors: Venkateshwar Rao Gummadi, Susanta Samajdar
-
Patent number: 11691987Abstract: The present invention provides bicyclic heterocyclyl kinase enzyme inhibitor compounds of formula (I), which are therapeutically useful as kinase inhibitors, particularly IRAK4 inhibitors. wherein A, Y, Z, X1, X2, X3, R1, R3, ‘m’, ‘n’ and ‘p’ have the meanings given in the specification and pharmaceutically acceptable salt or stereoisomer thereof that are useful in the treatment and prevention of diseases or disorder, in particular their use in diseases or disorder mediated by kinase enzyme, particularly IRAK4 enzyme. The present invention also provides pharmaceutical composition comprising at least one of the compounds of compound of formula (I) together with a pharmaceutically acceptable carrier, diluent or excipient therefor.Type: GrantFiled: April 30, 2021Date of Patent: July 4, 2023Assignee: Aurigene Discovery Technologies LimitedInventors: Venkateshwar Rao Gummadi, Susanta Samajdar
-
Publication number: 20230043159Abstract: The present invention provides compounds for inhibiting matriptase 2, or a mutant thereof, and compositions and methods of use thereof.Type: ApplicationFiled: October 2, 2019Publication date: February 9, 2023Inventors: Srikanth Venkatraman, Subhendu Mukherjee, Rajeev Goswami, Venkateshwar Rao Gummadi, A. Bharathi Raja, Martuza Hadianawala
-
Publication number: 20220339161Abstract: The present invention provides methods of treating hematological disorders, such as acute myeloid leukemia, using substituted heterocyclic compounds and pharmaceutically acceptable salts thereof. The compounds inhibit IRAK4 and FLT-3 kinases.Type: ApplicationFiled: June 29, 2022Publication date: October 27, 2022Inventors: Venkateshwar Rao Gummadi, Susanta Samajdar, Kavitha Nellore, Girish Daginakatte, Wesley Roy Balasubramanian
-
Patent number: 11419875Abstract: The present invention provides methods of treating hematological disorders, such as acute myeloid leukemia, using substituted heterocyclic compounds and pharmaceutically acceptable salts thereof. The compounds inhibit IRAK4 and FLT-3 kinases.Type: GrantFiled: March 30, 2018Date of Patent: August 23, 2022Assignee: Aurigene Discovery Technologies LimitedInventors: Venkateshwar Rao Gummadi, Susanta Samajdar, Kavitha Nellore, Girish Daginakatte, Wesley R. Balasubramanian
-
Publication number: 20220056046Abstract: The present invention provides bicyclic heterocyclyl kinase enzyme inhibitor compounds of formula (I), which are therapeutically useful as kinase inhibitors, particularly IRAK4 inhibitors. wherein A, Y, Z, X1, X2, X3, R1, R3, ‘m’, ‘n’ and ‘p’ have the meanings given in the specification and pharmaceutically acceptable salt or stereoisomer thereof that are useful in the treatment and prevention of diseases or disorder, in particular their use in diseases or disorder mediated by kinase enzyme, particularly IRAK4 enzyme. The present invention also provides pharmaceutical composition comprising at least one of the compounds of compound of formula (I) together with a pharmaceutically acceptable carrier, diluent or excipient therefor.Type: ApplicationFiled: April 30, 2021Publication date: February 24, 2022Inventors: Venkateshwar Rao Gummadi, Susanta Samajdar
-
Publication number: 20210290628Abstract: The present invention provides methods of treating hematological disorders, such as acute myeloid leukemia, using substituted heterocyclic compounds and pharmaceutically acceptable salts thereof. The compounds inhibit IRAK4 and FLT-3 kinases.Type: ApplicationFiled: March 30, 2018Publication date: September 23, 2021Applicant: Aurigene Discovery Technologies LimitedInventors: Venkateshwar Rao Gummadi, Susanta Samajdar, Kavitha Nellore, Girish Daginakatte, Wesley R. Balasubramanian
-
Patent number: 10995100Abstract: The present invention provides bicyclic heterocyclyl kinase enzyme inhibitor compounds of formula (I), which are therapeutically useful as kinase inhibitors, particularly IRAK4 inhibitors. wherein A, Y, Z, X1, X2, X3, R1, R3, ‘m’, ‘n’ and ‘p’ have the meanings given in the specification and pharmaceutically acceptable salt or stereoisomer thereof that are useful in the treatment and prevention of diseases or disorder, in particular their use in diseases or disorder mediated by kinase enzyme, particularly IRAK4 enzyme. The present invention also provides pharmaceutical composition comprising at least one of the compounds of compound of formula (I) together with a pharmaceutically acceptable carrier, diluent or excipient therefor.Type: GrantFiled: February 19, 2020Date of Patent: May 4, 2021Assignee: Aurigene Discovery Technologies LimitedInventors: Venkateshwar Rao Gummadi, Susanta Samajdar
-
Publication number: 20200190112Abstract: The present invention provides bicyclic heterocyclyl kinase enzyme inhibitor compounds of formula (I), which are therapeutically useful as kinase inhibitors, particularly IRAK4 inhibitors. wherein A, Y, Z, X1, X2, X3, R1, R3, ‘m’, ‘n’ and ‘p’ have the meanings given in the specification and pharmaceutically acceptable salt or stereoisomer thereof that are useful in the treatment and prevention of diseases or disorder, in particular their use in diseases or disorder mediated by kinase enzyme, particularly IRAK4 enzyme. The present invention also provides pharmaceutical composition comprising at least one of the compounds of compound of formula (I) together with a pharmaceutically acceptable carrier, diluent or excipient therefor.Type: ApplicationFiled: February 19, 2020Publication date: June 18, 2020Inventors: Venkateshwar Rao Gummadi, Susanta Samajdar
-
Patent number: 10640517Abstract: The present invention provides bicyclic heterocyclyl kinase enzyme inhibitor compounds of formula (I), which are therapeutically useful as kinase inhibitors, particularly IRAK4 inhibitors. wherein A, Y, Z, X1, X2, X3, R1, R3, ‘m’, ‘n’ and ‘p’ have the meanings given in the specification and pharmaceutically acceptable salt or stereoisomer thereof that are useful in the treatment and prevention of diseases or disorder, in particular their use in diseases or disorder mediated by kinase enzyme, particularly IRAK4 enzyme. The present invention also provides pharmaceutical composition comprising at least one of the compounds of compound of formula (I) together with a pharmaceutically acceptable carrier, diluent or excipient therefor.Type: GrantFiled: August 3, 2018Date of Patent: May 5, 2020Assignee: Aurigene Discovery Technologies LimitedInventors: Venkateshwar Rao Gummadi, Susanta Samajdar
-
Publication number: 20180370988Abstract: The present invention provides bicyclic heterocyclyl kinase enzyme inhibitor compounds of formula (I), which are therapeutically useful as kinase inhibitors, particularly IRAK4 inhibitors. wherein A, Y, Z, X1, X2, X3, R1, R3, ‘m’, ‘n’ and ‘p’ have the meanings given in the specification and pharmaceutically acceptable salt or stereoisomer thereof that are useful in the treatment and prevention of diseases or disorder, in particular their use in diseases or disorder mediated by kinase enzyme, particularly IRAK4 enzyme. The present invention also provides pharmaceutical composition comprising at least one of the compounds of compound of formula (I) together with a pharmaceutically acceptable carrier, diluent or excipient therefor.Type: ApplicationFiled: August 3, 2018Publication date: December 27, 2018Inventors: Venkateshwar Rao Gummadi, Susanta Samajdar
-
Patent number: 10160753Abstract: The present invention provides indazole compounds of formula (I), which are therapeutically useful as kinase inhibitors, particularly IRAK4 inhibitors, wherein Z1, Z2, R1, R2, R3, ‘m’ and ‘n’ have the meanings given in the specification, and pharmaceutically acceptable salts or stereoisomers thereof that are useful in the treatment and prevention of diseases or disorders, in particular their use in diseases or disorders mediated by kinase enzyme, particularly IRAK4 enzyme. The present invention also provides pharmaceutical compositions comprising at least one of the compounds of the compound of formula (I) together with a pharmaceutically acceptable carrier, diluent or excipient.Type: GrantFiled: January 7, 2015Date of Patent: December 25, 2018Assignee: Aurigene Discovery Technologies LimitedInventors: Venkateshwar Rao Gummadi, Susanta Samajdar, Ajay Gupta
-
Patent number: 10047104Abstract: The present invention provides bicyclic heterocyclyl kinase enzyme inhibitor compounds of formula (I), which are therapeutically useful as kinase inhibitors, particularly IRAK4 inhibitors. wherein A, Y, Z, X1, X2, X3, R1, R3, ‘m’, ‘n’ and ‘p’ have the meanings given in the specification and pharmaceutically acceptable salt or stereoisomer thereof that are useful in the treatment and prevention of diseases or disorder, in particular their use in diseases or disorder mediated by kinase enzyme, particularly IRAK4 enzyme. The present invention also provides pharmaceutical composition comprising at least one of the compounds of compound of formula (I) together with a pharmaceutically acceptable carrier, diluent or excipient therefor.Type: GrantFiled: August 2, 2017Date of Patent: August 14, 2018Assignee: Aurigene Discovery Technologies LimitedInventors: Venkateshwar Rao Gummadi, Susanta Samajdar
-
Publication number: 20180208605Abstract: The present invention provides substituted aza compounds of formula (I) or (II) and pharmaceutically acceptable salts thereof, and their use to inhibit IRAK-4 and/or for the treatment of diseases or disorders induced by IRAK-4.Type: ApplicationFiled: July 15, 2016Publication date: July 26, 2018Inventors: Venkateshwar Rao GUMMADI, Susanta SAMAJDAR, Subhendu MUKHERJEE, Mark Gary BOCK
-
Publication number: 20180201609Abstract: The present invention provides indazole and aza indazole compounds of formula (I) or (II) and pharmaceutically acceptable salts thereof, and their use to inhibit IRAK-4 and/or for the treatment of diseases or disorders induced by IRAK-4.Type: ApplicationFiled: July 14, 2016Publication date: July 19, 2018Inventors: Venkateshwar Rao Gummadi, Susanta Samajdar, Subhendu Mukherjee
-
Publication number: 20180022758Abstract: The present invention provides bicyclic heterocyclyl kinase enzyme inhibitor compounds of formula (I), which are therapeutically useful as kinase inhibitors, particularly IRAK4 inhibitors. wherein A, Y, Z, X1, X2, X3, R1, R3, ‘m’, ‘n’ and ‘p’ have the meanings given in the specification and pharmaceutically acceptable salt or stereoisomer thereof that are useful in the treatment and prevention of diseases or disorder, in particular their use in diseases or disorder mediated by kinase enzyme, particularly IRAK4 enzyme. The present invention also provides pharmaceutical composition comprising at least one of the compounds of compound of formula (I) together with a pharmaceutically acceptable carrier, diluent or excipient therefor.Type: ApplicationFiled: August 2, 2017Publication date: January 25, 2018Inventors: Venkateshwar Rao Gummadi, Susanta Samajdar
-
Patent number: 9732095Abstract: The present invention provides bicyclic heterocyclyl kinase enzyme inhibitor compounds of formula (I), which are therapeutically useful as kinase inhibitors, particularly IRAK4 inhibitors, wherein A, Y, Z, X1, X2, R1, R3, ‘m’, ‘n’ and ‘p’ have the meanings given in the specification and pharmaceutically acceptable salt or stereoisomer thereof that are useful in the treatment and prevention of diseases or disorder, in particular their use in diseases or disorder mediated by kinase enzyme, particularly IRAK4 enzyme. The present invention also provides pharmaceutical composition comprising at least one of the compounds of compound of formula (I) together with a pharmaceutically acceptable carrier, diluent or excipient therefor.Type: GrantFiled: January 12, 2015Date of Patent: August 15, 2017Assignee: Aurigene Discovery Technologies LimitedInventors: Venkateshwar Rao Gummadi, Susanta Samajdar
-
Publication number: 20170152263Abstract: The present invention provides substituted indazole compound of formula (I) and pharmaceutically acceptable salts thereof, and their use to inhibit IRAK4 and/or for the treatment of diseases or disorders induced by IRAK4.Type: ApplicationFiled: June 19, 2015Publication date: June 1, 2017Inventors: Venkateshwar Rao Gummadi, Susanta Samajdar
-
Publication number: 20160340366Abstract: The present invention provides bicyclic heterocyclyl kinase enzyme inhibitor compounds of formula (I), which are therapeutically useful as kinase inhibitors, particularly IRAK4 inhibitors, wherein A, Y, Z, X1, X2, R1, R3, ‘m’, ‘n’ and ‘p’ have the meanings given in the specification and pharmaceutically acceptable salt or stereoisomer thereof that are useful in the treatment and prevention of diseases or disorder, in particular their use in diseases or disorder mediated by kinase enzyme, particularly IRAK4 enzyme. The present invention also provides pharmaceutical composition comprising at least one of the compounds of compound of formula (I) together with a pharmaceutically acceptable carrier, diluent or excipient therefor.Type: ApplicationFiled: January 12, 2015Publication date: November 24, 2016Inventors: Venkateshwar Rao Gummadi, Susanta Samajdar